Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA PDD vs white-light cystoscopy for NMIBC detection
ChiCTR2600123199Phase 3Completed
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 5-aminolevulinic acid in bladder cancer and Bladder cancer in situ (CIS), sponsored by Shanghai General Hospital. Primary endpoint: Detection rate of NMIBC with PDD fluorescence vs white-light cystoscopy. Started Apr 2026; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
bladder cancerBladder cancer in situ (CIS)
Beyond the preview
Go deeper on ChiCTR2600123199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123199.